Abstract
More than 300 phase I clinical trials of gene therapy, involving over 2000 patients, have been initiated over the last 5 years: nearly two-thirds of these are for cancer. These trials have tested the feasibility and safety of gene transduction in patients, as well as identifying the problems involved. It is now clear that further research to improve efficiency and specificity of transduction and control of transgene expression will be necessary for more effective cancer gene therapy protocols. This group’s contribution to the gene therapy field has been to make a series of improvements in retroviral vectors, resulting in recombinant viruses with higher titer, resistant to human serum, and which are specifically targeted to tumor cells.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Boehm T, Folkman J, Browder T, O’Reilly MS (1997) Inhibition of tumour angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Nature 390: 404–407
Castleden SA, Chong H, Garcia-Ribas I, Melcher AA, Hutchinson G, Roberts B, Hart IR, Vile RG (1997) A family of bicistronic vectors to enhance both local and systemic antitumour effects of HSVtk or cytokine expression in a murine melanoma model. Hum Gene Ther 8: 2087–2102
Cosset FL, Takeuchi Y, Battini JL, Weiss RA, Collins MKL (1995) High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol 69: 7430–7436
Martin F, Neil S, Kupsch J, Maurice M, Cosset F-L, Collins MKL (1999) Retrovirus targeting by tropism restriction to melanoma cells. J Virol 73: 6923–6929
Miller DG, Adam MA, Miller AD (1990) Gene transfer by retroviral vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 10: 4239–4242
Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272: 263–267
Palmer K, Moore J, Everard M, Harris JD, Rodgers S, Rees RC, Murray AK, Mascari R, Kirkwood J, Riches PG, Fisher C, Thomas JM, Johnston SRD, Collins MKL, Gore ME (1999) Gene therapy with autologous, interleukin2-secreting tumour cells in patients with malignant melanoma increases circulating anti-tumour cytotoxic T lymphocytes. Hum Gene Ther 10: 1261–1268
Porter C, Lukacs K, Box G, Takeuchi Y, Collins MKL (1998) Cationic liposomes enhance the rate of transduction by a recombinant retroviral vector in vitro and in vivo. J Virol 72: 4832–4840
Takeuchi Y, Porter CD, Strahan KM, Preece AF, Gustafsson K, Cosset FL, Weiss RA, Collins MKL (1996) Sensitization of cells and retroviruses to human serum by alpha(1–3) galactosyltransferase. Nature 379: 85–88
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Collins, M. (2000). Retroviral Vectors for Cancer Gene Therapy. In: Walden, P., Sterry, W., Hennekes, H. (eds) Therapeutic Vaccination Strategies. Ernst Schering Research Foundation Workshop, vol 30. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-04183-3_6
Download citation
DOI: https://doi.org/10.1007/978-3-662-04183-3_6
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-04185-7
Online ISBN: 978-3-662-04183-3
eBook Packages: Springer Book Archive